Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Incyte Corporation
Groupe Oncologie Radiotherapie Tete et Cou
GERCOR - Multidisciplinary Oncology Cooperative Group
Merck Sharp & Dohme LLC
City of Hope Medical Center
Institute of Oncology Ljubljana
Austrian South Oncology Group
Presage Biosciences
Bristol-Myers Squibb
Assistance Publique Hopitaux De Marseille
UNICANCER
Wake Forest University Health Sciences
University of Chicago
Eli Lilly and Company
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Icahn School of Medicine at Mount Sinai
Sanofi
Memorial Sloan Kettering Cancer Center
Genentech, Inc.
Drexel University
University of Miami
University of Michigan Rogel Cancer Center
Lithuanian University of Health Sciences
Valerio Therapeutics
Stanford University
Radiation Therapy Oncology Group
University of Chicago
National Cancer Institute (NCI)
University of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
SCRI Development Innovations, LLC
Case Comprehensive Cancer Center
Sanofi
Galectin Therapeutics Inc.
Fudan University
SWOG Cancer Research Network
Sanofi
SCRI Development Innovations, LLC
Sanofi